Drug profile · INN
carvedilol phosphate
COREG CR
carvedilol phosphate (COREG CR) is a adrenergic receptor beta antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — carvedilol phosphate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 2
- Programs
- 0
- Data quality
- 0.84
Quick answer
carvedilol phosphate (COREG CR) is a adrenergic receptor beta antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Adrenergic receptor beta antagonist
Primary target: Adrenergic receptor alpha-1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Related patents
Frequently asked questions
What is carvedilol phosphate?
carvedilol phosphate (COREG CR) is a adrenergic receptor beta antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for carvedilol phosphate?
COREG CR is a marketed brand name for carvedilol phosphate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of carvedilol phosphate?
carvedilol phosphate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.